Estudio de utilización tipo indicación - prescripción del Diclofenaco en el tratamiento del cierre de conducto arterioso permeable
...
Martínez Cardozo, Luz Adriana | 2019
The ductus arteriosus is a vascular structure that connects the proximal descending aorta with the main pulmonary artery near the origin of the pulmonary branch, (Ruiz, D; et al. 2008) and that results in a pulmonary diversion during fetal life. This duct must be closed for a maximum of 3 days in full-term newborns (RNT), but in certain cases this closure does not occur naturally, this is called as Permeable Arterial Conduit (CAP) CIE-10 Q250, and must originate its closure pharmacologically or surgically. Currently, Diclofenac and Acetaminophen are used in the treatment of Permeable Arterial Duct Closure, however, there is no record that has the approved indication for use in this pathology, therefore this is considered a Use Not Indicated in the Sanitary Registry (UNIRS).
Because there is currently no study on the use of Diclofenac in the treatment of CAP, this work was developed in order to generate a study of use type indication - prescription of Diclofenac, to provide information about the conditions of use of this medication and its safety profile.
When characterizing the use of Diclofenac in patients aged 0 to 1 in Colombia during the period from 2014 to 2017, a total of 208 reported cases were found of patients diagnosed with CAP whose pharmacological treatment was Diclofenac, where 107 cases they belong to the female sex and 101 correspond to male patients; These cases were presented mostly in the city of Bogotá D.C., with a total of 88 cases reported. At the same time, when comparing the safety profile of Diclofenac and Acetaminophen, it was found that Acetaminophen has a lower percentage of adverse reactions; therefore, it has a better safety profile. Thanks to this last deduction, the UNIRS form for Acetaminophen was made, evaluating different characteristics such as efficacy, safety, pharmacokinetics, benefits and risks of using this medication as a therapy for the treatment of patent ductus arteriosus duct closure
LEER